OKYO Pharma’s Surprise Move: Cancels Public Offering Plans

OKYO Pharma’s Bold Move: Pulls the Plug on Public Offering Amid Shifting Market Tides

LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a dynamic player in the ophthalmology-focused bio-pharmaceutical arena, is making waves once again. The company, renowned for its pursuit of innovative solutions, has been on the cusp of introducing OK-101—a groundbreaking treatment for dry eye disease (DED), addressing a substantial gap in a market worth billions.

However, in a surprising turn of events, OKYO Pharma has officially announced the cancellation of its highly-anticipated public offering of ordinary shares. Additionally, the company has severed ties with Freedom Capital Markets, its chosen underwriter for this venture. The driving force behind this strategic decision? The ever-evolving landscape of market dynamics.

It’s a decision that underscores the agility and adaptability of OKYO Pharma, always ready to navigate the changing tides of the industry. While this may mark a shift in their immediate plans, it reflects their unwavering commitment to delivering the best possible outcomes for patients and stakeholders.

As they say, in the world of biopharmaceuticals, one must be prepared to pivot when the seas get rough. OKYO Pharma stands ready for the next exciting chapter in its journey, promising even more groundbreaking advancements on the horizon.

This press release serves as a testament to OKYO Pharma’s dedication to its mission and its determination to make a meaningful impact in the world of healthcare. Stay tuned for what’s next in their quest to redefine ophthalmology treatment.

About OKYO Pharma

At the forefront of innovation, OKYO Pharma Limited (Nasdaq: OKYO) is a trailblazing life sciences company dedicated to unearthing and nurturing groundbreaking molecules. Their mission? To pave the way for transformative treatments in the realms of inflammatory dry eye diseases and chronic pain. With a relentless commitment to redefining healthcare, OKYO Pharma is the vanguard of cutting-edge research and development, poised to reshape the future of medicine.

Forward-Looking Statements

In the realm of possibilities, let it be known that this announcement contains the seeds of the future. These aren’t just statements; they are windows into what lies ahead. Picture a canvas where the Company paints its aspirations, guided by its current understanding, beliefs, and assumptions. Look for the words that carry the torch of anticipation, expectation, intention, and belief—these are the markers of our forward-looking journey.

But remember, this is no crystal ball. There are no guarantees, only the winds of uncertainty that can sway the course. Beyond our control, lurking in the shadows, are the known and unknown risks, elusive uncertainties, and other forces that could rewrite the script, leading to outcomes different from our dreams.

To those who lend an ear, let caution be your ally. Do not hang all your hopes on these forward-looking visions, for they are but snapshots of a moment in time. They relate only to the here and now, as of this very announcement. The road ahead is uncertain, and we make no promises to unveil every twist and turn.

Yet, in this ever-evolving narrative, we pledge to remain transparent and accountable. We’ll keep you informed should our path diverge from these forward-looking markers. We do so not just as a legal obligation but as a commitment to the future we’re shaping, one step at a time.

Leave a Comment